Vaccitech, a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in its PCA001 clinical trial. The study is designed to determine the efficacy and safety of VTP-850 monotherapy in men with rising PSA after definitive local therapy for prostate cancer. VTP-850 is a next-generation immunotherapeutic candidate that uses two proprietary non-replicating viral vectors to target four prostate-associated antigens: PSA, PAP, STEAP1 and 5T4. The first phase of the trial is enrolling participants in the US, with plans to open further sites in Italy and Spain. Prostate cancer affects millions worldwide and there are limited treatment options available.
The PCA001 clinical trial by Vaccitech aims to evaluate the safety and effectiveness of VTP-850 monotherapy on men with rising PSA after definitive local therapy for their disease. This multi-centre Phase 1/2 clinical trial will utilize Vaccitech's sequential dosing approach using two proprietary nonreplicating viral vectors, ChAdOx and MVA. Previous trials have shown promising data from VTP-800, which encoded 5T4 antigen expressed by most prostate cancers. VTP-850 is a multi-antigen immunotherapeutic candidate containing